Answers are grounded in this paper and cite their sources.
Original research identifies ECG changes and cardiac involvement in Fabry disease, suggesting critical intervention points.
Abstract Background Cardiac involvement of the disease is a leading cause of death and disability in Fabry disease characterized by pathological accumulation of globotriaosylceramide (Gb3) and lyso-globotriaosylceramide (lyso-Gb3) in multiple organs. In this study, we sought to investigate the electrocardiographic (ECG) changes in different clinical stages and evaluate the value of these parameters in assessing cardiac involvement. Methods 62 patients with Fabry disease and 45 healthy controls were recruited in this study. ECG assessment, echocardiographic assessment and cardiac magnetic resonance (CMR) were recorded at rest in the same day. We defined 4 clinical stages of Fabry disease cardiomyopathy according to echocardiographic assessment and CMR: Pre-detectable stage, Non-hypertrophic stage, Hypertrophic and pre-fibrotic stage as well as Hypertrophic and fibrotic stage. Results Our results showed that Tp-e/QT was significantly decreased and Sokolow-Lyon index was markedly increased following the development of disease. QRS width and Tp-e/QT was associated with the severity of cardiac involvement in Fabry disease. Conclusions Our results demonstrated that QRS width and Tp-e/QT were associated with the severity of cardiac involvement in patients with Fabry disease and contributed to define the optimal intervention timepoint and assess the severity of cardiac involvement and response to disease-specific therapies.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: